Updated Price Disclosure Guidelines

By Petrina Smith
Tuesday, 26 November, 2013


An updated version of the Price Disclosure Arrangements Procedural and Operational Guidelines for Expanded and Accelerated Price Disclosure has been published.
The updated Guidelines reflect changes made to the National Health (Pharmaceutical  Benefits) Regulations 1960 in April 2013. According to the Department of Health website, those Regulation changes were made following December 2012 litigation concerning inclusion of de-listed brands in price disclosure calculations.  The Guidelines also provide more information about a number of other matters, including:



  • how to disclose data when the commercial responsibility for a brand passes before the legally responsible person has been changed;

  • calculating new premiums for price disclosure reductions;

  • how price disclosure reductions are applied to new brands listing after the end of a data collection period and before the reduction day;


and

  • how reduced prices are adjusted to take account of any change in pricing quantity for brands of a pharmaceutical item between the end of the data collection period and the reduction day


Find out more at http://www.pbs.gov.au/info/industry/pricing/eapd#Explanatory
Related Articles

Oral care and the prevention of hospital-acquired pneumonia: new evidence for infection prevention and control practice

The HAPPEN randomised control trial involved 8870 patients across three Australian hospitals. Two...

"Pointless scans" to diagnose knee osteoarthritis may trigger inappropriate care, the Commission warns

The warning is informed by the Australian Commission on Safety and Quality in Health Care's...

"Hell in a handbasin": infection considerations of four handbasin design features

An Australian-led review has compared healthcare handbasin design guidelines across 39 countries...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd